Claims for Patent: 8,182,812

Summary for Patent: 8,182,812

Title:	Human monoclonal antibodies against CD25
Abstract:	Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Inventor(s):	Schuurman; Janine (Amsterdam, NL), Havenith; Catharina Emanuele Gerarda (Bodegraven, NL), Parren; Paul (Odijk, NL), Van De Winkel; Jan G. J. (Zeist, NL), Williams; Denise Leah (San Jose, CA), Petersen; Jorgen (Rungsted Kyst, DK), Baadsgaard; Ole (Malmo, SE)
Assignee:	Genmab A/S (Copenhagen, DK)
Application Number:	12/283,775
Patent Claims:	1. A method of inhibiting proliferation of an activated T cell expressing CD25, wherein the T cell is associated with an autoimmune disorder, transplant rejection, or graft-versus-host disease, comprising administering a monoclonal antibody that binds human CD25, such that proliferation of the cell is inhibited, wherein the antibody is selected from the group consisting of: (a) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 35, 36, and 37, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 38, 39, and 40, respectively; (b) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 17, 18 and 19, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively; (c) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively; (d) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 32, 33, and 34, respectively; (e) an antibody having heavy and light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO: 6 and SEQ ID NO: 8, respectively; (f) an antibody having heavy and light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO: 14 and SEQ ID NO: 16, respectively; (g) an antibody having a heavy chain and a light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO: 2 and SEQ ID NO: 4, respectively; and (h) an antibody having a heavy chain and a light chain variable regions comprising the amino acid sequences as set forth in SEQ ID NO: 10 and SEQ ID NO: 12, respectively. 2. A method of inhibiting proliferation of an activated T cell expressing CD25, wherein the T cell is associated with an autoimmune disorder, transplant rejection, or graft-versus-host disease, comprising administering a monoclonal antibody that binds human CD25, such that the proliferation of the cell is inhibited, wherein the antibody binds to an epitope on human CD25 defined by the antibody selected from the group consisting of: (a) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 35, 36, and 37, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 38, 39, and 40, respectively; (b) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 17, 18 and 19, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively; (c) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively; and (d) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 32, 33, and 34, respectively. 3. A method of inhibiting proliferation of an activated T cell expressing CD25, wherein the T cell is associated with an autoimmune disorder, transplant rejection, or graft-versus-host disease, comprising administering a monoclonal antibody that binds human CD25, such that proliferation of the cell is inhibited, wherein the antibody has the binding characteristics of the antibody selected from the group consisting of: (a) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 35, 36, and 37, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 38, 39, and 40, respectively; (b) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 17, 18 and 19, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 20, 21, and 22, respectively; (c) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 23, 24, and 25, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 26, 27, and 28, respectively; and (d) an antibody comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences comprising the amino acid sequences set forth in SEQ ID NOs: 32, 33, and 34, respectively. 4. The method of any one of claims 1, 2, or 3, further comprising separately administering another therapeutic agent or therapy. 5. The method of claim 4, wherein the therapeutic agent is an immunosuppressant selected from the group consisting of cyclosporine, azathioprine, mycophenolic acid, mycophenolate mofetil, a corticosteroid, methotrexate, gold salts, sulfasalazine, an antimalarial, brequinar, leflunomide, mizoribine, 15-deoxyspergualine, 6-mercaptopurine, cyclophosphamide, rapamycin, tacrolimus (FK-506), OKT3, and anti-thymocyte globulin. 6. The method of claim 4, wherein the therapeutic agent is an anti-inflammatory agent selected from the group consisting of a steroidal drug, a NSAID (nonsteroidal anti-inflammatory drug), and a DMARD, hydroxychloroquine, sulfasalazine, leflunomide, an IL-1 receptor blocking agent, a TNF-.alpha. blocking agent, an anti-IL-6R antibody, CTLA4Ig, and an anti-IL-15 antibody. 7. The method of claim 4, wherein the therapeutic agent is selected from the group consisting of coal tar, A vitamin, anthralin, calcipotrien, tarazotene, corticosteroids, methotrexate, a retinoid, cyclosporine, etanercept, alefacept, efaluzimab, 6-thioguanine, mycophenolate mofetil, tacrolimus (FK-506), hydroxyurea, doxorubicin, cisplatin, bleomycin, carmustine, chlorambucil, and cyclophosphamide. 8. The method of claim 4, wherein the therapy is phototherapy. 9. The method of any one of claims 1, 2, or 3, wherein the antibody is an IgG1 or IgG4 antibody. 10. The method of any one of claims 1, 2, or 3, wherein the antibody dissociates from human CD25 with a dissociation equilibrium constant (K.sub.D) of 10.sup.-8 M to 10.sup.-11 M, when determined by surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using human recombinant CD25 as the ligand and the antibody as the analyte. 11. The method of any one of claims 1, 2, or 3, wherein the antibody is a fragment or a single chain antibody. 12. The method of any one of claims 1, 2, or 3, wherein the antibody further comprises a chelator linker for attaching a radioisotope. 13. The method of any one of claims 1, 2, or 3, wherein the antibody is human, humanized, or chimeric. 14. The method of any one of claims 1, 2, or 3, wherein the T cell is associated with an autoimmune disorder. 15. The method of any one of claims 1, 2, or 3, wherein the T cell is associated with transplant rejection. 16. The method of any one of claims 1, 2, or 3, wherein the T cell is associated with graft-versus-host disease. 17. The method of any one of claims 1, 2, or 3, wherein the T cell is associated with a disorder selected from the group consisting of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, type 1 diabetes, insulin-requiring type 2 diabetes, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, dermato-polymyositis, Sjogren's syndrome, arteritides, including giant cell arteritis, aplastic anemia, asthma, scleroderma, and uveitis.

Details for Patent 8,182,812

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2039-03-29
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007		2039-03-29
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017		2039-03-29
Immunex Corporation	ENBREL	etanercept	Injection	103795			2039-03-29